Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BG505 SOSIP.664 gp140 Booster in Healthy Adults
NCT05863585Phase 1Unknown
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Recombinant Protein Vaccines, Fc-Fusion Proteins
01
Overview
Phase 1, open-label, single-arm trial of BG505 SOSIP.664 gp140 in human immunodeficiency virus infection (HIV), sponsored by International AIDS Vaccine Initiative. Primary endpoint: Safety and tolerability of BG505 SOSIP.664 gp140 Vaccine at 1 year. Status: unknown.
02
Drugs
BG505 SOSIP.664 gp140
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05863585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05863585.